Stock VKTX VIKING THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Viking Therapeutics, Inc.

Equities

VKTX

US92686J1060

Market Closed - Nasdaq
Other stock markets
 21:00:00 14/05/2024 BST 		Pre-market 14:06:59
72.5 USD +0.21% Intraday chart for Viking Therapeutics, Inc. 72.86 +0.50%
05-06 Viking Therapeutics Insider Sold Shares Worth $4,986,008, According to a Recent SEC Filing MT
05-03 Wall St set to open sharply higher on soft jobs data RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
6 Stocks Positioned to Soar as Investors Focus on MASH
AQ
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
PR
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
PR
Viking Therapeutics Announces $632.5 Million Public Offering Of Common Stock
AQ
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
PR
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
PR
Viking Therapeutics Announces Proposed Public Offering of Common Stock
PR
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
PR
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024
PR
Viking Therapeutics to Participate at Upcoming Investor Conferences
PR
Adrenoleukodystrophy Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
PR
Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023
PR
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
PR
Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
PR
Viking Therapeutics to Participate at Upcoming Investor Conferences
PR
Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
PR
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
PR
Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VKTX Stock
  4. News Viking Therapeutics, Inc.
  5. Press Releases